Results 201 to 210 of about 264,196 (349)
Pediatric Discovery, EarlyView.The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R‐CHOP) is the first‐line treatment for non‐Hodgkin lymphoma (NHL). Nine articles involving 331 patients were included in the meta‐analysis, the pooled proportion of reproductive adverse events was 22.3% (95% CI 11.4%–33.2%; p < 0.001). The findings
Rong Han +6 more
wiley +1 more source
Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions
British Journal of Clinical Pharmacology, EarlyView., 2023 Abstract Despite 2 h of daily exercise training, muscle wasting and bone loss are still present after 6‐month missions to the international space station. Some crew members lose bone much faster than others. In preparation for missions to the Moon and Mars, space agencies are therefore reviewing their countermeasure portfolios.
Friederike Thomasius +2 more
wiley +1 more source
Menopause and Diabetes Risk Along with Trajectory of β-Cell Function and Insulin Sensitivity: A Community-Based Cohort Study. [PDF]
Healthcare (Basel)Choi MJ, Yu J.
europepmc +1 more source
Portal Hypertension &Cirrhosis, EarlyView.The advantages to measure handgrip strength (HGS) are simple, convenient, noninvasive, cost‐effective, and easy to be widely carried out during daily clinical practice. Mounting evidence demonstrates that muscle strength measured by HGS is a feasible and reliable metric to evaluate nutritional status, as well as relevant cirrhosis‐related complications
Binxin Cui, Ziyi Yang, Chao Sun
wiley +1 more source
Cervical Cancer Screening After Menopause. [PDF]
Healthcare (Basel)Tung HJ +3 more
europepmc +1 more source
Clinical and endocrinological investigations on superovulation induced in heifers by human menopausal gonadotrophin [PDF]
, 1982 A. Lauria +6 more
openalex +1 more source
Small, EarlyView.This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai +5 more
wiley +1 more source
Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects [PDF]
, 1989 I.L. Crighton +4 more
openalex +1 more source